

Name: Dr. Tripti Mishra

Date of joining DBT-CIAB: 01/07/2022

Current Designation: Research Associate

Email ID: tripti.mishra@ciab.res.in; triptimishra.0803@gmail.com



Educational Qualification:

- **2014-2019:** Ph.D (Natural Product and Medicinal Chemistry) [CSIR- Central Drug Research Institute, Lucknow, Uttar Pradesh, India]
- **2010-2012:** M.Sc (Organic Chemistry) [Ramjas College, University of Delhi, New Delhi, India]
- **2007-2010:** B.Sc (Chemistry Honors) [St. Xavier's College, Ranchi, Jharkhand, India]

Awards and Fellowships

- Qualified **CSIR-NET**, 2013 (All India Rank 61)
- Qualified **GATE**, 2013
- Received **Dr M M Dhar Memorial Distinguished Career Achievement Award** in Chemical Sciences 2020, CSIR-CDRI
- Received **Incentive Awards for Technology** 2020, CSIR-CDRI
- Received **Incentive award for Excellence in Research Publications** 2022, CSIR-CDRI

Publications:

- Gupta S*, **Mishra T***, Varshney S, Vinita K, Khandelwal N, Rai P, Garg P, Dev K, Gupta A, Kumar D, Balaramnavar VM, Arya Kr, Gayen JR, Narender T, Gaikwad AN. Coelogen ameliorates metabolic dyshomeostasis by regulating adipogenesis and enhancing energy expenditure in adipose tissue. *Pharmacological Research*, 2021, 172, 105776, doi: 10.1016/j.phrs.2021.105776 (**Impact factor- 10.334**)
- Chhabra S, **Mishra T**, Kumar Y, Thacker G, Kanojiya S, Chattopadhyay N, Narender T, Trivedi AK. Chebulinic Acid isolated from the fruits of *Terminalia chebula* specifically induces apoptosis in acute myeloid leukemia cells. *Phytotherapy Research*, 2017, 31,1849-1857, doi: 10.1002/ptr.5927 (**Impact factor- 6.388**)
- Sharma A*, **Mishra T***, Thacker G, Mishra M, Narender T, Trivedi AK. Chebulinic acid inhibits MDA-MB-231 breast cancer metastasis and promotes cell death through down regulation of SOD1 and induction of autophagy. *Cell Biology International*, 2020, 44, 2553-2569, doi: 10.1002/cbin.11463 (**Impact factor- 4.473**)
- Prakash R*, **Mishra T***, Dev K*, Sharma K, Kuldeep J, John Aa, Tripathi A, Sharma C, Arya KR, Kumar B, Siddiqi MI, Narender T, Singh D. Phenanthrenoid Coelogen isolated from *Coelogyne cristata* exerts osteoprotective effect through MAPK - Mitogen-Activated Protein Kinase signaling pathway. *Calcified Tissue International*, 2021, 109, 32-43, doi: 10.1007/s00223-021-00818-3 (**Impact factor- 4.000**)
- Sharma R, Srivastava T, Pandey AR, **Mishra T**, Gupta B, Reddy SS, Singh SP, Narender T Tripathi A, Chandramouli B, Sashidhara KV, Priya S, Kumar N.

Identification of natural products as potential pharmacological chaperones for protein misfolding diseases. *ChemMedChem*, 2021, 16, 2146-2156, doi: 10.1002/cmdc.202100147 (**Impact factor- 3.540**)

(* **denotes equal contribution**)

Abstracts/Posters (presented in national/international conferences):

- Delivered Oral Presentation on “**Chebulinic acid isolated from the fruits of Terminalia chebula specifically induces apoptosis in acute myeloid leukemia cells**” at DDNPTM-2018, held at NIPER- Mohali, India from 15-17 November 2018

Patent and License of Product

- Patent entitled “Chebulinic acid and its enriched fraction from the fruits of Terminalia chebula for the management of Benign Prostatic Hyperplasia (BPH) and its purification and preparation thereof” has been published on 17.03.2022 (International application no. : **PCT/IN2021/050898**; International publication no. : **WO 2022/054100 A1**)
- Licence agreement has been signed between CSIR-CDRI and Lumen Marketing Company, Chennai on “Standardized fraction enriched with compound N-012-0001 for the management of Benign Prostatic Hyperplasia” on 17.02.2019